ELQ-331 as a prototype for extremely durable chemoprotection against malaria

BACKGROUND: The potential benefits of long-acting injectable chemoprotection (LAI-C) against malaria have been recently recognized, prompting a call for suitable candidate drugs to help meet this need. On the basis of its known pharmacodynamic and pharmacokinetic profiles after oral dosing, ELQ-331,...

Descripción completa

Detalles Bibliográficos
Autores principales: Smilkstein, Martin J., Pou, Sovitj, Krollenbrock, Alina, Bleyle, Lisa A., Dodean, Rozalia A., Frueh, Lisa, Hinrichs, David J., Li, Yuexin, Martinson, Thomas, Munar, Myrna Y., Winter, Rolf W., Bruzual, Igor, Whiteside, Samantha, Nilsen, Aaron, Koop, Dennis R., Kelly, Jane X., Kappe, Stefan H. I., Wilder, Brandon K., Riscoe, Michael K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712883/
https://www.ncbi.nlm.nih.gov/pubmed/31455339
http://dx.doi.org/10.1186/s12936-019-2921-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712883/
https://www.ncbi.nlm.nih.gov/pubmed/31455339
http://dx.doi.org/10.1186/s12936-019-2921-9

Ejemplares similares